The Middle East gastric cancer diagnostics market size was estimated at USD 25.68 million in 2024 and is projected to reach USD 48.04 million by 2033, growing at a CAGR of 7.32% from 2025 to 2033. Growth in the gastric cancer diagnostics market in the Middle East is driven by rising disease burden and delayed detection rates, which are fueling demand for early screening and molecular testing. Strategic initiatives such as Mylab-AstraGene’s 2023 partnership in the UAE and Kuwait, Guardant Health-Hikma’s 2024 collaboration to expand liquid biopsy access, and the UAE’s 2025 approval of Biomerica’s Fortel H. pylori test are enhancing diagnostic capacity. In addition, biomarker adoption, including Claudin 18.2 testing at Burjeel Medical City in 2025, underscores increasing precision oncology integration
The gastric cancer diagnostics market in the Middle East is entering a period of accelerated growth, supported by significant regulatory approvals, commercial partnerships, and increasing healthcare investment. Although the overall incidence of gastric cancer in the region is lower compared to East Asia, late detection and limited survival rates are creating strong demand for early diagnostic solutions and precision oncology. Recent developments highlight how the market is evolving across screening, molecular diagnostics, and companion testing.
A major milestone came in March, 2023, when Mylab Discovery Solutions partnered with AstraGene in the UAE and Kuwait. This collaboration focuses on the co-development of automated molecular diagnostic solutions, including reagents, kits, and fully automated platforms. The initiative is expected to reduce reliance on imports, improve affordability, and build local capacity to meet the rising demand for oncology testing. Localized manufacturing also ensures compliance with regional regulatory frameworks and supports hospitals and laboratories with faster access to advanced molecular technologies.
This product will be delivered within 1-3 business days.
The gastric cancer diagnostics market in the Middle East is entering a period of accelerated growth, supported by significant regulatory approvals, commercial partnerships, and increasing healthcare investment. Although the overall incidence of gastric cancer in the region is lower compared to East Asia, late detection and limited survival rates are creating strong demand for early diagnostic solutions and precision oncology. Recent developments highlight how the market is evolving across screening, molecular diagnostics, and companion testing.
A major milestone came in March, 2023, when Mylab Discovery Solutions partnered with AstraGene in the UAE and Kuwait. This collaboration focuses on the co-development of automated molecular diagnostic solutions, including reagents, kits, and fully automated platforms. The initiative is expected to reduce reliance on imports, improve affordability, and build local capacity to meet the rising demand for oncology testing. Localized manufacturing also ensures compliance with regional regulatory frameworks and supports hospitals and laboratories with faster access to advanced molecular technologies.
Middle East Gastric Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East gastric cancer diagnostics market report based on product, disease, end use, and country:Product Outlook (Revenue, USD Million, 2021-2033)
- Reagents & Consumables
- Instruments
Disease Outlook (Revenue, USD Million, 2021-2033)
- Adenocarcinoma
- Gastric lymphoma
- Others
End-Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Diagnostic Laboratories
- Diagnostic Imaging
Country Outlook (Revenue, USD Million, 2021-2033)
- Middle East
- South Africa
- UAE
- Kuwait
- Oman
- Qatar
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. ME Gastric Cancer Diagnostics Market Variables, Trends & Scope
Chapter 4. ME Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis
Chapter 5. ME Gastric Cancer Diagnostics Market: Disease Estimates & Trend Analysis
Chapter 6. ME Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 7. ME Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Middle East Gastric Cancer Diagnostics market report include:- MiRXES Pte Ltd
- Agilent Technologies Inc
- Endofotonics Pte Ltd
- Bio-Rad Laboratories, Inc
- Hipro Biotechnology Co., Ltd
- F. Hoffmann-La Roche Ltd.
- Exact Sciences Corporation
- QIAGEN
- Fulgent Genetics
- Abbott
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 25.68 Million |
| Forecasted Market Value ( USD | $ 48.04 Million |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
